Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia

American Journal of Hematology

Volumn 89, Issue 1, 2014, Pages 68-73

  Marchetti, Marina ^a   Tartari, Carmen J ^a   Russo, Laura ^a   Panova Noeva, Marina ^a   Leuzzi, Annamaria ^a   Rambaldi, Alessandro ^a   Finazzi, Guido ^a   Woodhams, Barry ^b   Falanga, Anna ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b HaemaCon Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIGEN; BLOOD CLOTTING FACTOR 7A; HYDROXYUREA; JANUS KINASE 2; PHENYLALANINE; PHOSPHOLIPID; PROCOAGULANT; TF ANTIGEN; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ARTICLE; CALIBRATED AUTOMATED THROMBOGRAM; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE FREE PLASMA; THROMBOCYTHEMIA; THROMBOELASTOGRAPHY; THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; FACTOR VIIA; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PHOSPHOLIPIDS; THROMBIN; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPLASTIN; YOUNG ADULT;

EID: 84892843806     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23590     Document Type: Article

References (25)

1. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:285-293.
2. Falanga A, Marchetti M, Barbui T, et al. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils. Semin Hematol 2005;42:239-247.
3. Marchetti M, Falanga A. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol Haemost Thromb 2008;36:148-159.
4. Cheung B, Radia D, Pantelidis P, et al. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006;132:244-245.
5. Lussana F, Caberlon S, Pagani C, et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review. Thromb Res 2009;124:409-417.
6. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266.
7. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-175.
8. Trappenburg MC, van Schilfgarade M, Marchetti M, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009;94:911-918.
9. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008;34:683-691.
10. Morel O, Jessel L, Freyssinet JM, et al. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011;31:15-26.
11. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011;108:1284-1297.
12. Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res 2012;129(Suppl 1):S132-S136.
13. Davizon P, Lopez JA. Microparticles and thrombotic disease. Curr Opin Hematol 2009;16:334-341.
14. Thiele J, Kvasnicka HM. [Chronic myeloproliferative disorders. The new WHO classification]. Pathologe 2001;22:429-443.
15. Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008;112:4061-4068.
16. Duchemin J, Ugo V, Ianotto JC, et al. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 2010;126:238-242.
17. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011;29:3179-3184.
18. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-2313.
19. Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: Relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007;35:702-711.
20. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 2009;84:102-108.
21. Panova-Noeva M, Marchetti M, Spronk HM, et al. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 2011;86:337-342.
22. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
23. Haubold K, Rink M, Spath B, et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009;101:1147-1155.
24. Campello E, Spiezia L, Radu CM, et al. Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. Thromb Haemost 2012;108:633-639.
25. Italiano JE Jr, Mairuhu AT, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 2010;17:578-584.